The company reported strong earnings in the second quarter of 2025. It posted revenue of $11.1 billion, which showed a 7.37% ...

We came across a bullish thesis on Abbott Laboratories on r/ValueInvesting subreddit by anonymous_sheep1. In this article, we ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, ...

We recently published Jim Cramer Discusses These 10 Stocks & AI-Led Disinflation. Abbott Laboratories (NYSE:ABT) is one of ...

Abbott Laboratories ABT is preparing to release its quarterly earnings on Thursday, 2025-07-17. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Abbott posted Q2 revenue of $11.14 billion and EPS of $1.26, raised 2025 earnings guidance, and saw strong growth in diabetes ...

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories closed 12.43% short of its 52-week high of $141.23, which the company reached on March 4th.

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

The healthcare-products maker trimmed and narrowed its guidance for the year while reporting strong profit and sales gains in the second quarter.

Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.